Seegene

Seegene Receivables

The Accounts Receivable of Seegene (096530.KQ) as of Nov 3, 2026 is 109.11 B KRW. In the previous year, Accounts Receivable was 338.64 B KRW — a change of -67.78% (lower).

Receivables

109.11 BKRW

YoY

-67.78%

Last updated:

Accounts Receivable of Seegene is 2022 109.11 B KRW. Accounts Receivable of Seegene was 2021 338.64 B KRW. It decreases by -67.78% lower compared to the previous year.

The Seegene Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2015
55.41 B KRW
Jan 1, 2016
52.17 B KRW
Jan 1, 2017
49.94 B KRW
Jan 1, 2018
39.65 B KRW
Jan 1, 2019
44.07 B KRW
Jan 1, 2020
266.48 B KRW
Jan 1, 2021
338.64 B KRW
Jan 1, 2022
109.11 B KRW
The Seegene Receivables history
YEARReceivablesYoY
109.11 BKRW-67.78%
338.64 BKRW+27.08%
266.48 BKRW+504.72%
44.07 BKRW+11.13%
39.65 BKRW-20.59%
49.94 BKRW-4.28%
52.17 BKRW-5.84%
55.41 BKRW+10.54%
50.12 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

Accounts Receivable of Seegene is 109.11 B KRW in 2022.

Accounts Receivable of Seegene changed from 338.64 B KRW to 109.11 B KRW, representing a -67.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Seegene since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Seegene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Seegene

All Key Metrics — Seegene